{"id":3115,"date":"2026-09-14T08:00:00","date_gmt":"2026-09-14T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3115"},"modified":"2026-09-14T20:29:30","modified_gmt":"2026-09-15T00:29:30","slug":"destiny-lung04-shows-pfs-benefit-with-survival-unresolved","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3115","title":{"rendered":"DESTINY-Lung04 Shows PFS Benefit With Survival Unresolved"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Daiichi Sankyo and AstraZeneca<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase III)<\/p>\n

Modality<\/strong><\/p>\n

Antibody-Drug Conjugate (HER2-directed, topoisomerase-I inhibitor payload)<\/p>\n

Asset<\/strong><\/p>\n

Trastuzumab Deruxtecan<\/p>\n

Target<\/strong><\/p>\n

HER2 (exon 19\/20 mutations)<\/p>\n

Disease Area<\/strong><\/p>\n

HER2-Mutant Advanced Non-Small Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

First-line trastuzumab deruxtecan extended blinded-review median progression-free survival to 14.3 from 8.3 months versus pembrolizumab plus platinum-pemetrexed in the randomized Phase III DESTINY-Lung04 trial. Response rate was 70.0% versus 44.5%. The result establishes a clear disease-control advantage in HER2-mutant advanced NSCLC, but overall survival was immature and showed no observed benefit, while drug-related interstitial lung disease or pneumonitis occurred in 20.8% and was fatal in four patients.<\/p>\n

DESTINY-Lung04 randomized 454 patients with unresectable locally advanced or metastatic non-squamous NSCLC carrying HER2 exon 19 or 20 mutations to trastuzumab deruxtecan 5.4 mg\/kg or pembrolizumab plus platinum-pemetrexed. Median PFS was 14.3 versus 8.3 months (HR 0.63; 95% CI 0.50\u20130.79; P<0.0001). Objective response was 70.0% versus 44.5%, median response duration 13.4 versus 9.7 months, and PFS2 22.7 versus 17.3 months (HR 0.80; 95% CI 0.62\u20131.02).<\/p>\n

At 46.9% overall-survival maturity, formal testing was not performed. Median OS was 29.3 versus 33.1 months (HR 1.15; 95% CI 0.88\u20131.52). Subsequent HER2-directed therapy was used in 48.0% of control patients versus 23.3% of trastuzumab-deruxtecan patients. Grade 3 or higher treatment-related adverse events occurred in 34.1% in the experimental arm. Adjudicated drug-related ILD\/pneumonitis occurred in 20.8%, including five grade 3, one grade 4, and four grade 5 events.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that direct HER2 targeting should replace immunochemotherapy as the first-line disease-control standard. The large randomized PFS and response advantages, global enrollment, and mechanistic continuity with second-line efficacy support that view. Against it stand immature survival, an unfavorable current OS point estimate, and fatal ILD. A second interpretation is that post-progression treatment imbalance diluted a true survival advantage. Greater subsequent HER2-directed use in the control arm supports that possibility, but postrandomization therapy cannot erase the intent-to-treat result or establish causation. Mature OS and sensitivity analyses are required.<\/p>\n

Company and Product Background<\/h4>\n

Daiichi Sankyo and AstraZeneca jointly develop trastuzumab deruxtecan, an HER2-directed antibody\u2013drug conjugate carrying a topoisomerase-I inhibitor payload through a cleavable linker. HER2 exon 19\/20 mutations are oncogenic drivers in a small subset of NSCLC. The drug is already used after prior systemic therapy in HER2-mutant advanced NSCLC; DESTINY-Lung04 tests movement into the initial metastatic setting.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The data strengthen regulatory expansion and first-line adoption prospects while moving ILD prevention and early recognition to the center of benefit-risk assessment.<\/li>\n
  • Upgrades if:<\/strong> later OS trends toward benefit, CNS and mutation-subgroup effects remain consistent, and fatal ILD decreases with monitoring and management.<\/li>\n
  • Downgrades if:<\/strong> OS remains unfavorable, PFS2 loses coherence, or pulmonary toxicity concentrates in clinically unavoidable subgroups.<\/li>\n
  • Falsified if:<\/strong> mature survival and quality-of-life evidence fail to offset serious treatment-related harm relative to immunochemotherapy.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    DESTINY-Lung04 is a decisive PFS trial and an incomplete survival trial. The strongest supported conclusion is that trastuzumab deruxtecan delays progression more effectively than immunochemotherapy in this molecular population. It is too early to claim superior overall clinical benefit, and four fatal ILD events materially constrain the positive efficacy signal.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 5\/5 \u2014 global randomized Phase III evidence against the first-line standard. Importance:<\/strong> High \u2014 tests a change to first-line standard of care in a molecularly defined NSCLC population. Confidence:<\/strong> High on facts, moderate on interpretation \u2014 partner disclosures provide concordant efficacy and safety tables, but net survival benefit is not yet established.<\/p>\n","protected":false},"excerpt":{"rendered":"

    First-line trastuzumab deruxtecan extended blinded-review median progression-free survival to 14.3 from 8.3 months versus pembrolizumab plus platinum-pemetrexed in the randomized Phase III DESTINY-Lung04 trial. Response rate was 70.0% versus 44.5%. The result establishes a…<\/p>\n","protected":false},"author":1,"featured_media":3135,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[16,752,18,358],"class_list":["post-3115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-astrazeneca","tag-daiichi-sankyo","tag-non-small-cell-lung-cancer","tag-trastuzumab-deruxtecan"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3115"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3115\/revisions"}],"predecessor-version":[{"id":3141,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3115\/revisions\/3141"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3135"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}